Bullous pemphigoid after inactivated
            <scp>COVID</scp>
            ‐19 vaccination: Case report

Zhang, Yingjie; Lang, Xiaoqing; Guo, Shuangshuang; He, Hongqing; Cui, Hongzhou

doi:10.1111/dth.15595

Cited by 8 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Bullous pemphigoid is the most frequently reported autoimmune blistering disorder appearing after COVID-19 vaccination. 2 Pemphigus was less frequently associated with vaccination. 3 Our patient was remarkable as she had a chronic and relapsing disease that failed to meet the diagnostic criteria of pemphigus, pemphigoid, or any other auto-immune blistering disorder.…”

Section: Subepidermal Bullous Eruptions Following Vaccination Representmentioning

confidence: 85%

“…Animal Studies: N/A. Noureddine Litaiem MD 1,2 Azza Ghannem MD 1,2 Amal Chabbouh MD 1,2 Soumaya Rammeh MD 2,3 Maryam Sellami MD 2,4 Faten Zeglaoui MD…”

Section: Co N Fli C T O F I Nter E S T S Tatem Entmentioning

confidence: 99%

“…Subepidermal bullous eruptions following vaccination represent an immune‐mediated event related to nonspecific off‐target immune response 1 . Bullous pemphigoid is the most frequently reported auto‐immune blistering disorder appearing after COVID‐19 vaccination 2 . Pemphigus was less frequently associated with vaccination 3 .…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Atypical subepidermal blistering disease following COVID‐19 vaccination

Litaiem,

Ghannem,

Chabbouh

et al. 2023

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

show abstract

Section: Subepidermal Bullous Eruptions Following Vaccination Representmentioning

confidence: 85%

“…Animal Studies: N/A. Noureddine Litaiem MD 1,2 Azza Ghannem MD 1,2 Amal Chabbouh MD 1,2 Soumaya Rammeh MD 2,3 Maryam Sellami MD 2,4 Faten Zeglaoui MD…”

Section: Co N Fli C T O F I Nter E S T S Tatem Entmentioning

confidence: 99%

See 1 more Smart Citation

Atypical subepidermal blistering disease following COVID‐19 vaccination

Litaiem,

Ghannem,

Chabbouh

et al. 2023

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

show abstract

“…DPP-4 inhibitors were suspended in patients using these medications [34,44,45,48]. Intravenous immunoglobulin G (IVIG) was administered in selected cases, and biologics, such as dupilumab and omalizumab, were utilized [26,34,49,55,56]. Rituximab was introduced in three cases, leading to significant improvement [51,56,63].…”

Section: Treatment and Outcomes For New-onset Aibd Or Aibd Flaresmentioning

confidence: 99%

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Wu,

Huang,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background: Cases of autoimmune bullous dermatosis (AIBD) have been reported following COVID-19 vaccination. Objective: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination. Methods: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting ≥ 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine. Results: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation. Conclusions: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.

show abstract

“…Considering the recent global outbreak of the coronavirus disease 2019 (COVID-19) pandemic, various types of vaccines have been widely administered [5]. Consequently, numerous reports documenting diverse discomforts experienced by vaccinated individuals have emerged [6][7][8][9][10][11][12]. Some patients have reported experiencing oral lesions or exacerbations of pre-existing oral lesions following vaccination [6,7].…”

Section: Immunopathological Findings Include Histopathologic Examinat...mentioning

confidence: 99%

Drug-Induced Bullous Pemphigoid Associated with the Severe Acute Respiratory Syndrome-Coronavirus Disease 2019 Vaccine: Case Report

Park,

Kim,

Ahn

et al. 2023

J Oral Med Pain

View full text Add to dashboard Cite

In this study, we investigate the emergence of bullous pemphigoid (BP) after the administration of the Severe Acute Respiratory Syndrome-Coronavirus Disease 2019 (SARS-COVID-19) vaccine. The study presents two cases of women, aged 47 and 53, diagnosed with BP following SARS-COVID-19 vaccination. BP is a common autoimmune blistering disorder prevalent among older populations, with an incidence rate ranging from 2 to 40 cases per million individuals. This condition arises when autoantibodies target adhesive proteins in the skin, resulting in blister formation and mucosal erosion. Drug-induced bullous pemphigoid (DIBP) shares similarities with the classic form of BP but may be influenced by medication usage. Notably, DIBP exhibits distinct characteristics, such as affecting a younger demographic and involving mucosal regions more prominently than classic BP. The growing incidence of BP is linked to factors such as an aging population and the rise of drug-induced cases. This case report provides valuable insights into comprehending DIBP, elucidating post-vaccination discomforts, particularly those related to oral lesions and the exacerbation of existing lesions. By elucidating these aspects, we aim to advance the understanding of DIBP within the medical community.

show abstract

Bullous pemphigoid after inactivated COVID ‐19 vaccination: Case report

Cited by 8 publications

References 10 publications

Atypical subepidermal blistering disease following COVID‐19 vaccination

Atypical subepidermal blistering disease following COVID‐19 vaccination

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Drug-Induced Bullous Pemphigoid Associated with the Severe Acute Respiratory Syndrome-Coronavirus Disease 2019 Vaccine: Case Report

Contact Info

Product

Resources

About